CME in Minutes: Education in Primary Care

Please visit answersincme.com/ZSN860 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Wanda Phipatanakul, MD, MS. In this activity, an expert in pediatric asthma discusses how to identify type 2 inflammation and tailor biologic therapy for pediatric patients with asthma. Upon completion of this activity, participants should be better able to: Identify the impact of type 2 inflammation on lung function in pediatric patients with asthma; Recognize best practices for incorporating biologics into the treatment of type 2 inflammatory pediatric asthma; and Outline the role of multidisciplinary teams in optimizing outcomes for pediatric patients with type 2 inflammatory asthma. This activity is intended for US healthcare professionals only.

Please visit answersincme.com/JJK860 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Rajsekar (Raj) Rajaraman, MD, MS. In this activity, an expert in pediatric neurology discusses the diagnosis and management of CDKL5 deficiency disorder. Upon completion of this activity, participants should be better able to: Describe key clinical characteristics that contribute to the burden of CDKL5 deficiency disorder (CDD); Evaluate the role of timely diagnosis in influencing care decisions for individuals with CDD; and Outline therapeutic approaches for managing seizures associated with CDD.

Please visit answersincme.com/860/104092969-replay to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Beth Faiman, PhD, MSN, APN-BC, TCTCN, AOCN, FAAN, FAPO; and Jesus Berdeja, MD. In this activity, experts in hematology-oncology discuss the evolving role of cereblon E3 ligase modulators (CELMoDs) in patients with relapsed/refractory multiple myeloma (RRMM). Upon completion of this activity, participants should be better able to: Identify the role of CELMoDs in the treatment of patients with RRMM. Utilize evidence-based practical strategies for the management of key adverse events associated with CELMoDs in patients with RRMM. Apply key considerations to support the integration of CELMoDs into the treatment paradigm for patients with RRMM.

Please visit answersincme.com/860/CME-26-207477-replay to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Vallerie V. McLaughlin, MD; and Richard Channick, MD. In this activity, experts in pulmonary arterial hypertension (PAH) discuss strategies for personalized risk-based intensification of therapy for patients with PAH. Upon completion of this activity, participants should be better able to: Describe the rationale for risk-based treatment intensification strategies in patients with PAH. Identify clinical indicators warranting escalation of therapy in patients with intermediate- or high-risk PAH. Outline an evidence-based, personalized approach to integrating novel add-on therapies into treatment plans for patients with PAH. undefined In this activity, experts in pulmonary arterial hypertension (PAH) discuss strategies for personalized risk-based intensification of therapy for patients with PAH.

Please visit answersincme.com/860/014832-replay to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Anne E. O'Donnell, MD; andPatrick Flume, MD. In this activity, experts in bronchiectasis discuss best practices for identifying, diagnosing, and treating CF and non-CF bronchiectasis. Upon completion of this activity, participants should be better able to:Distinguish between underlying causes of bronchiectasis that provide the rationale for targeting neutrophil inflammation. Outline recommended multidisciplinary strategies to promptly recognize and diagnose bronchiectasis. Describe the design and eligibility criteria of ongoing trials evaluating neutrophil-targeted therapies for bronchiectasis. This session is supported by Boehringer Ingelheim Pharmaceuticals, Inc. Exhibitors and supporters of NACFC include manufacturers of CF drugs, medical device companies, pharmacies, hospitals, and other related organizations. The Cystic Fibrosis Foundation does not support nor endorse the products or services of NACFC 2026 exhibitors and supporters.

Please visit answersincme.com/860/160204757-replay to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Karen P. Acker, MD; and Donna Hallas, PhD, PPCNP-PC, CPNP, PMHS, FAANP, FAAN. In this activity, experts in RSV prevention discuss the latest evidence and practical strategies for implementing immunoprophylaxis and coordinating caregiver counseling across the care continuum. Upon completion of this activity, participants should be better able to: Discuss the rationale for RSV immunoprophylaxis for preventing RSV disease in early infancy. Integrate guideline recommendations into shared clinical decision-making for the prevention of RSV in infants. Outline the complementary roles of pre- and postnatal clinicians in coordinating RSV immunization counseling across the care continuum. Implement coordinated communication strategies to support caregiver decision-making about RSV prevention. This symposium is not sponsored, endorsed or accredited by the American Academy of Pediatrics.

Please visit answersincme.com/CJF860 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Manuel Rodriguez-Justo, MBBCh, MSc, MD, FRCPath; and Elizabeth Smyth, MD, FRCP. In this activity, experts in oncology and pathology discuss the impact of claudin 18.2 (CLDN18.2) tests and treatments for patients with advanced gastric or gastroesophageal junction cancers. Upon completion of this activity, participants should be better able to: Describe the rationale for CLDN18.2 testing in patients with advanced gastric and gastroesophageal junction cancers (GC/GEJC); Review the potential clinical impact of emerging CLDN18.2-targeted antibody-drug conjugates (ADCs) for the treatment of GC/GEJC; and Outline evidence-based, emerging strategies to optimize outcomes in patients with advanced GC/GEJC.

Please visit answersincme.com/QRE860 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Theresa W. Guilbert, MD, MS. In this activity, an expert in childhood asthma discusses the use of biologics for moderate to severe pediatric asthma. Upon completion of this activity, participants should be better able to: Identify the impact of type 2 inflammation on lung function in pediatric patients with asthma; Recognize best practices for incorporating biologics into the treatment of type 2 inflammatory pediatric asthma; and Review the clinical profiles of biologic therapies for type 2 inflammatory asthma in pediatric patients. This activity is intended for US healthcare professionals only.

Please visit answersincme.com/MSM860 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Ritu Salani, MD; and Courtney Arn, CNP. In this activity, experts in gynecological oncology discuss antibody-drug conjugates (ADCs) in ovarian, cervical, and endometrial cancers. Upon completion of this activity, participants should be better able to: Describe the rationale for using ADCs in previously treated patients with gynecologic cancers; Assess the safety and tolerability evidence for approved ADC therapies in gynecologic cancers; Formulate management strategies for adverse events associated with ADC treatment of ovarian, cervical, and endometrial cancers; and Outline patient-centered approaches to facilitate adherence with ADC therapy.

Please visit answersincme.com/FSP860 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Jay N. Yepuri, MD, MS, FACG, FTSGE. In this activity, an expert in gastroenterology discusses molecular prognostics tests that predict the risk of progression from Barrett’s esophagus (BE) to esophageal adenocarcinoma (EAC). Upon completion of this activity, participants should be better able to: Describe the limitations of traditional approaches to predicting risk of progression to EAC for patients with BE; Review the evolving role of advanced molecular prognostic tests in assessing risk of progression to EAC in patients with BE; and Outline multidisciplinary strategies to integrate advanced molecular prognostic tests into the management of patients with BE.

Please visit answersincme.com/WAY860 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Elizabeth O'Donnell, MD. In this activity, an expert in multi-cancer early detection (MCED) discusses strategies to apply MCED testing into everyday clinical practice. Upon completion of this activity, participants should be better able to: Discuss the benefits and risks of MCED testing; and Outline patient-centered strategies to appropriately incorporate MCED testing into the primary care setting.

Please visit answersincme.com/BVK860 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Jesus E. Pina-Garza, MD. In this activity, an expert in epilepsy discusses recognizing seizure emergencies, selecting appropriate rescue treatments and routes of administration, and developing individualized seizure action plans. Upon completion of this activity, participants should be better able to: Define seizure emergencies based on expert consensus to support accurate treatment decisions; Evaluate approved therapeutic approaches for the management of seizure clusters in the home/community setting; and Identify strategies to support the timely use of acute seizure medications through patient-centered seizure action plans.

Please visit answersincme.com/860/cvdprostate-replay to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Michael Cookson, MD; Alicia Morgans, MD, MPH; and Avirup Guha, MD, MBBS, MPH, FAHA, FACC, FESC, FICOS. In this activity, experts in prostate cancer discuss cardiovascular risk in patients receiving androgen-deprivation therapy (ADT). Upon completion of this activity, participants should be better able to: Evaluate the impacts of prostate cancer and ADT on cardiovascular risk; Translate the latest research for cardiovascular management of patients on ADT to clinical practice; and Design personalized treatment approaches to optimize ADT across treatment settings.

Please visit answersincme.com/NHB860 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Zev Wainberg, MD. In this activity, an expert in oncology discusses the use of TROP2-directed antibody-drug conjugates (ADCs) across solid tumors. Upon completion of this activity, participants should be better able to: Review the rationale for targeting TROP2 with antibody-drug conjugates (ADCs) across tumor stages and settings; Evaluate the clinical profiles of available and emerging TROP-targeting ADCs across tumor stages and settings; and Apply evidence-based strategies to recognize and monitor treatment-related adverse events (TRAEs) associated with ADCs.

Please visit answersincme.com/TZA860 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by James E. Galvin, MD, MPH. In this activity, an expert in Alzheimer’s disease (AD) discusses treatment of early AD with anti-amyloid therapies. Upon completion of this activity, participants should be better able to: Review the latest advances in anti-amyloid therapies for the treatment of early Alzheimer’s disease (AD; Assess the current evidence on anti-amyloid therapies, including maintenance strategies, for the treatment of early AD; and Outline strategies to integrate the latest advances in anti-amyloid therapies to practice to improve long-term outcomes for patients with early AD.

Please visit answersincme.com/BHT860 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Sara Stafford, MDCM, FRCPC and Gihane Zarifa, MD, CCFP, FCFP, MSc. In this activity, experts in family medicine and endocrinology discuss the role of oral glucagon-like peptide-1 (GLP-1) receptor agonists (RAs) in personalized type 2 diabetes (T2D) management. Upon completion of this activity, participants should be better able to: Discuss individualized, guideline-informed management strategies for T2D that address glycemic control, weight, and patient-specific factors; Differentiate key pharmacologic, administration, and tolerability characteristics of oral GLP-1 RAs to support patient counseling in T2D; and Interpret clinical evidence for approved and emerging oral GLP-1 RAs to inform their potential role in addressing gaps in T2D management.

Please visit answersincme.com/RVH860 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Vivien Brown, MDCM, CCFP, FCFP, MSCP. In this activity, an expert in menopause management in primary care discusses identification and treatment of menopause-related vasomotor symptoms (VMS). Upon completion of this activity, participants should be better able to: Integrate communication about menopause and VMS into routine patient encounters; Review treatment options for moderate to severe VMS, including NK receptor antagonists, with patients using a shared decision-making approach; and Formulate strategies for optimally monitoring patients who are receiving NK receptor antagonists for menopause-related VMS.

Please visit answersincme.com/860/MED-RESP-04317-replay to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Cecelia Damask, DO; Zara M. Patel, MD; Maria Colandrea, DNP, NP-C, CORLN, FAANP; and Dan Shaltanis. In this activity, experts in chronic rhinosinusitis with nasal polyps discuss the latest evidence and practical strategies for optimizing the use of biologic therapies and delivering patient-centered care. Upon completion of this activity, participants should be better able to: Review guideline recommendations for the use of biologic therapies to treat patients with chronic rhinosinusitis with nasal polyps (CRSwNP); Differentiate among biologic therapies for patients with CRSwNP based on clinical evidence; and Outline strategies to optimize the holistic management of CRSwNP.

Please visit answersincme.com/SJN860 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Jewel M. Kling, MD, MPH and Genevieve Neal-Perry, MD, PhD. In this activity, experts in menopause management discuss unmet therapeutic needs, emerging evidence for neurokinin (NK) receptor antagonists, and patient-focused strategies for managing menopause-associated vasomotor symptoms (VMS). Upon completion of this activity, participants should be better able to: Recognize unmet therapeutic needs among patients with menopause-associated VMS; Assess the evidence for nonhormonal therapies targeting NK receptors in the treatment of menopause-associated VMS; and Formulate patient-focused strategies for the optimal use of NK receptor antagonists for menopause-associated VMS.

Please visit answersincme.com/JKK860 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Alison J. Birtle, FRCP, FRCR, MD; and Niklas Klümper, MD. In this activity, experts in oncology discuss systemic therapies for locally advanced and metastatic urothelial carcinoma. Upon completion of this activity, participants should be better able to: Assess the evidence for recommended systemic treatment regimens for patients with LA/mUC in the context of treatment guidelines; Propose appropriate patient assessment strategies to guide systemic therapy decisions; and Formulate individualized treatment strategies to optimize outcomes for patients with LA/mUC using recommended first-line systemic treatments.